4.0 Article

Hematologically important mutations: X-linked chronic granulomatous disease (third update)

Journal

BLOOD CELLS MOLECULES AND DISEASES
Volume 45, Issue 3, Pages 246-265

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bcmd.2010.07.012

Keywords

gp91(phox); Chronic granulomatous disease; Mutation; CYBB; NADPH oxidase; X-linked disease

Categories

Funding

  1. CGD Research Trust, London, UK
  2. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2005/59568]
  3. Slovenian Research Agency [L3-0624]
  4. National Cancer Institute, National Institutes of Health [HHSN261200800001E]

Ask authors/readers for more resources

Chronic granulomatous disease (CGD) is an immunodeficiency disorder affecting about 1 in 250,000 individuals. The disease is caused by a lack of superoxide production by the leukocyte enzyme NADPH oxidase. Superoxide is used to kill phagocytosed micro-organisms in neutrophils, eosinophils, monocytes and macrophages. The leukocyte NADPH oxidase is composed of five subunits, of which the enzymatic component is gp91-phox, also called Nox2. This protein is encoded by the CYBB gene on the X chromosome. Mutations in this gene are found in about 70% of all CGD patients. This article lists all mutations identified in CYBB in the X-linked form of CGD. Moreover, apparently benign polymorphisms in CYBB are also given, which should facilitate the recognition of future disease-causing mutations. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available